View Financial HealthXTL Biopharmaceuticals 배당 및 자사주 매입배당 기준 점검 0/6XTL Biopharmaceuticals 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-23.5%자사주 매입 수익률총 주주 수익률-23.5%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 02XTL Biopharmaceuticals Ltd. announced delayed 20-F filingOn 04/30/2026, XTL Biopharmaceuticals Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.공시 • Apr 30XTL Biopharmaceuticals Ltd. (TASE:XTLB) entered into a definitive share purchase agreement to acquire Psyga Bio Ltd from the current shareholders.XTL Biopharmaceuticals Ltd. (TASE:XTLB) entered into a definitive share purchase agreement to acquire Psyga Bio Ltd from the current shareholders on April 28, 2026. Pursuant to the Purchase Agreement, XTL Biopharmaceuticals will acquire from the current shareholders of Psyga all of the issued and outstanding share capital of Psyga on a fully diluted basis in exchange for the issuance by XTL Biopharmaceuticals to the current shareholders of Psyga, by way of a private placement, of such number of ADSs of the Company representing, immediately after such issuance, 40% of the issued and outstanding share capital of XTL Biopharmaceuticals. In addition, as part of the Transaction, the shareholders of Psyga will be issued additional ADSs representing 10% of the issued and outstanding share capital of the Company as of the effective date of the Purchase Agreement upon the achievement of each of three (3) milestones (each, a “Milestone”): (i) the commencement of at least three (3) clinical trials with human patients of certain products from Psyga’s pipeline within twelve (12) months following the closing of the Transaction; (ii) the successful achievement of targets in at least two (2) clinical trials with human patients of certain products from Psyga’s pipeline within thirty-six (36) months following the closing of the Transaction; and (iii) entering the development of Ibogaine-based products triggered by execution of a binding commercialization agreement and/or development partnership agreement with a reputable third-party pharmaceutical, biotechnology, or life sciences company for the commercialization, licensing, development and/or co-development of Ibogaine-based products based on the Company’s regulatory licenses. XTL Biopharmaceuticals's audit committee and board of directors approved the Transaction. The Purchase Agreement contains customary representations and warranties, agreements and obligations and conditions to closing, all as are customary for transactions of this nature, including, without limitation, the approval of the Transaction by the Company’s shareholders and receipt of necessary government or third-party approvals, if required. I.F.S. Consulting and Investments Ltd acted as fairness opinion provider for XTL Biopharmaceuticals Ltd. Ronen Kantor of Amit, Pollak, Matalon & Co. acted as legal advisor for XTL Biopharmaceuticals Ltd. Yariv Reichenberg of Weksler, Bregman & Co. Advocates acted as legal advisor for Psyga Bio Ltd.공시 • Jan 14XTL Biopharmaceuticals Ltd. (TASE:XTLB) signed a letter of intent to acquire 85% stake in NeuroNos Limited from Beyond Air, Inc. (NasdaqCM:XAIR).XTL Biopharmaceuticals Ltd. (TASE:XTLB) signed a letter of intent to acquire 85% stake in NeuroNos Limited from Beyond Air, Inc. (NasdaqCM:XAIR) on January 13, 2026. A cash consideration of $1 million will be paid by XTL Biopharmaceuticals Ltd. The consideration consists of American Depositary Shares of XTL Biopharmaceuticals Ltd. to be issued as shall be required for Beyond Air, Inc. to beneficially own, as of the closing date of the Transaction, 19.99% of the issued and outstanding share capital of XTL Biopharmaceuticals Ltd. and three-year warrants of XTL Biopharmaceuticals Ltd. to be issued in such amount as necessary to ensure that Beyond Air, Inc. shall continue to maintain the Beneficial Ownership in relation to the exercise of certain existing XTL Biopharmaceuticals Ltd. warrants and any other issuances to employees and officers of NeuroNOS. Cash milestone payments in an aggregate amount of up to US$5,500,000, subject to the achievement of certain specified clinical and regulatory milestones, with an option for XTL Biopharmaceuticals Ltd., under certain circumstances, to discharge all such milestone payment obligations by making a single lump sum cash payment of US$4,000,000. Additionally, the LOI includes the payment of commercial milestone amounts by XTL Biopharmaceuticals Ltd. to Beyond Air, Inc based on cumulative net sales of the first NeuroNOS product, ranging from US$2,000,000 to US$12,500,000, upon attainment of specified net sales thresholds. Hence, XTL Biopharmaceuticals Ltd. will pay an earnout/contingent payment of $18 million cash. As part of consideration, $19 million is paid towards common equity of NeuroNos Limited. The transaction will be financed through equity investment of $2 million. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, consummation of due diligence investigation, definitive agreement and third party approval needed. The LOI contemplates that XTL intends to extend to the other shareholders of NeuroNOS, who collectively hold approximately 15% of the issued and outstanding share capital of NeuroNOS not owned by XAIR, the opportunity, exercisable within a specified period following the consummation of the Transaction, to exchange their Remaining Shares for ordinary shares of XTL, on terms and conditions to be set forth in the definitive agreements.공시 • Apr 07XTL Biopharmaceuticals Ltd. Announces Chief Executive Officer ChangesXTL Biopharmaceuticals Ltd. announced the appointment of Noam Band as the Company's new Chief Executive Officer. Mr. Band replaces Shlomo Shalev who will continue as the Chairman of the Board of Directors. Previously, Mr. Band has served as the Chairman and Chief Executive Officer of Gix Internet Ltd. (formerly Algomizer Ltd.) a publicly traded technology company specializing in online marketing, and as the Chief Executive Officer of Dotomi (acquired by ValueClick), where he oversaw operations and strategic initiatives in the digital marketing space. From 2020 through its acquisition in 2023 he served as a board advisor to 7digital Group plc (formerly AIM: 7DIG), contributing to its strategic direction and corporate governance. He has also served as the Chief Executive Officer of Monitor2Heart, and also served as a Chairman of Viewbix Inc. (OTCMKTS: VBIX) from 2018 to 2020. He holds an MBA and a B.A. in Economics from The Hebrew University of Jerusalem.공시 • Aug 16XTL Biopharmaceuticals Ltd. (TASE:XTLB) completed the acquisition of THE SOCIAL PROXY Ltd.XTL Biopharmaceuticals Ltd. (TASE:XTLB) entered into a binding term sheet to acquire THE SOCIAL PROXY Ltd. on March 19, 2024. In exchange, the XTL will issue a certain number of ADS's to Social Proxy shareholders, representing 44.6% of the company's share capital. Additionally, the company will pay $0.43 million to the shareholders of Social Proxy. The completion of the Transaction is subject to negotiation of definitive agreements, containing representations, warranties and covenants as well as the satisfaction of various conditions required prior to closing, all as are customary for transactions of this nature, including, without limitation, the satisfaction of the Company, in its sole discretion, of a due diligence into Social Proxy, the approval of the Transaction by the Company’s shareholders and receipt of necessary government or third-party approvals, if required. As of June 5, 2024, XTL Biopharmaceuticals Ltd. entered into a definitive share purchase agreement to acquire THE SOCIAL PROXY Ltd. In addition, as part of the Transaction, the shareholders of Social Proxy will be issued additional warrants, which may only be exercised upon reaching certain financial measured milestones within a period of up to three years from the closing of the Transaction. As per terms, Social Proxy will operate as fully owned subsidiary of the Company and its shareholders will be entitled to appoint two representatives to the Company’s board of directors out of a total of up to seven directors. XTL Biopharmaceuticals Ltd. (TASE:XTLB) completed the acquisition of THE SOCIAL PROXY Ltd. on August 14, 2024.공시 • Jul 23XTL Biopharmaceuticals Ltd., Annual General Meeting, Jul 22, 2024XTL Biopharmaceuticals Ltd., Annual General Meeting, Jul 22, 2024. Location: doron tikotzky kantor gutman & amit gross, 7 metsada st., b.s.r tower 4, 33 floor, bnei brak Israel공시 • Oct 21XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyXTL Biopharmaceuticals Ltd. announced that the Company received a written notification from the Nasdaq Stock Market LLC on October 18, 2023, notifying the Company that it is not in compliance with the minimum bid price requirement set in the Nasdaq Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of USD 1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's American Depositary Shares for the 30 consecutive business days from September 6, 2023, to October 17, 2023, the Company no longer meets the minimum bid price requirement. The Notification Letter does not impact the Company's listing on the Nasdaq Capital Market at this time and the Company's ADSs continue to trade on the Nasdaq Capital Market under the symbol "XTLB". In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until April 15, 2024, to regain compliance. The Notice states that to regain compliance, the bid price for the ADSs must close at USD 1.00 per ADS or more for a minimum of ten (10) consecutive business days during the compliance period ending April 15, 2024. In the event the Company does not regain compliance during the compliance period, the Company may be eligible for additional time. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse share split, if necessary. If the Company meets tese requirements, Nasdaq will inform the Company it has been granted an additional 180 calendar days to regain compliance with Nasdaq's current listing requirements. However, if it appears to Nasdaq that the Company will not be able to cure this deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company's securities will be subject to delisting. The Company will continuously monitor the closing bid price of its ADSs between now and April 15, 2024, and will evaluate its options to regain compliance with Nasdaq Listing Rule 5550(a)(2) before such date. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price or maintain compliance with other Nasdaq listing standards.New Risk • Jun 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$6.56m market cap). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 XTLB 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: XTLB 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장XTL Biopharmaceuticals 배당 수익률 vs 시장XTLB의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (XTLB)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Biotechs)2.4%분석가 예측 (XTLB) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 XTLB 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 XTLB 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 XTLB 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: XTLB 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 02:41종가2026/05/22 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스XTL Biopharmaceuticals Ltd.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Swayampakula RamakanthH.C. Wainwright & Co.
공시 • May 02XTL Biopharmaceuticals Ltd. announced delayed 20-F filingOn 04/30/2026, XTL Biopharmaceuticals Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
공시 • Apr 30XTL Biopharmaceuticals Ltd. (TASE:XTLB) entered into a definitive share purchase agreement to acquire Psyga Bio Ltd from the current shareholders.XTL Biopharmaceuticals Ltd. (TASE:XTLB) entered into a definitive share purchase agreement to acquire Psyga Bio Ltd from the current shareholders on April 28, 2026. Pursuant to the Purchase Agreement, XTL Biopharmaceuticals will acquire from the current shareholders of Psyga all of the issued and outstanding share capital of Psyga on a fully diluted basis in exchange for the issuance by XTL Biopharmaceuticals to the current shareholders of Psyga, by way of a private placement, of such number of ADSs of the Company representing, immediately after such issuance, 40% of the issued and outstanding share capital of XTL Biopharmaceuticals. In addition, as part of the Transaction, the shareholders of Psyga will be issued additional ADSs representing 10% of the issued and outstanding share capital of the Company as of the effective date of the Purchase Agreement upon the achievement of each of three (3) milestones (each, a “Milestone”): (i) the commencement of at least three (3) clinical trials with human patients of certain products from Psyga’s pipeline within twelve (12) months following the closing of the Transaction; (ii) the successful achievement of targets in at least two (2) clinical trials with human patients of certain products from Psyga’s pipeline within thirty-six (36) months following the closing of the Transaction; and (iii) entering the development of Ibogaine-based products triggered by execution of a binding commercialization agreement and/or development partnership agreement with a reputable third-party pharmaceutical, biotechnology, or life sciences company for the commercialization, licensing, development and/or co-development of Ibogaine-based products based on the Company’s regulatory licenses. XTL Biopharmaceuticals's audit committee and board of directors approved the Transaction. The Purchase Agreement contains customary representations and warranties, agreements and obligations and conditions to closing, all as are customary for transactions of this nature, including, without limitation, the approval of the Transaction by the Company’s shareholders and receipt of necessary government or third-party approvals, if required. I.F.S. Consulting and Investments Ltd acted as fairness opinion provider for XTL Biopharmaceuticals Ltd. Ronen Kantor of Amit, Pollak, Matalon & Co. acted as legal advisor for XTL Biopharmaceuticals Ltd. Yariv Reichenberg of Weksler, Bregman & Co. Advocates acted as legal advisor for Psyga Bio Ltd.
공시 • Jan 14XTL Biopharmaceuticals Ltd. (TASE:XTLB) signed a letter of intent to acquire 85% stake in NeuroNos Limited from Beyond Air, Inc. (NasdaqCM:XAIR).XTL Biopharmaceuticals Ltd. (TASE:XTLB) signed a letter of intent to acquire 85% stake in NeuroNos Limited from Beyond Air, Inc. (NasdaqCM:XAIR) on January 13, 2026. A cash consideration of $1 million will be paid by XTL Biopharmaceuticals Ltd. The consideration consists of American Depositary Shares of XTL Biopharmaceuticals Ltd. to be issued as shall be required for Beyond Air, Inc. to beneficially own, as of the closing date of the Transaction, 19.99% of the issued and outstanding share capital of XTL Biopharmaceuticals Ltd. and three-year warrants of XTL Biopharmaceuticals Ltd. to be issued in such amount as necessary to ensure that Beyond Air, Inc. shall continue to maintain the Beneficial Ownership in relation to the exercise of certain existing XTL Biopharmaceuticals Ltd. warrants and any other issuances to employees and officers of NeuroNOS. Cash milestone payments in an aggregate amount of up to US$5,500,000, subject to the achievement of certain specified clinical and regulatory milestones, with an option for XTL Biopharmaceuticals Ltd., under certain circumstances, to discharge all such milestone payment obligations by making a single lump sum cash payment of US$4,000,000. Additionally, the LOI includes the payment of commercial milestone amounts by XTL Biopharmaceuticals Ltd. to Beyond Air, Inc based on cumulative net sales of the first NeuroNOS product, ranging from US$2,000,000 to US$12,500,000, upon attainment of specified net sales thresholds. Hence, XTL Biopharmaceuticals Ltd. will pay an earnout/contingent payment of $18 million cash. As part of consideration, $19 million is paid towards common equity of NeuroNos Limited. The transaction will be financed through equity investment of $2 million. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, consummation of due diligence investigation, definitive agreement and third party approval needed. The LOI contemplates that XTL intends to extend to the other shareholders of NeuroNOS, who collectively hold approximately 15% of the issued and outstanding share capital of NeuroNOS not owned by XAIR, the opportunity, exercisable within a specified period following the consummation of the Transaction, to exchange their Remaining Shares for ordinary shares of XTL, on terms and conditions to be set forth in the definitive agreements.
공시 • Apr 07XTL Biopharmaceuticals Ltd. Announces Chief Executive Officer ChangesXTL Biopharmaceuticals Ltd. announced the appointment of Noam Band as the Company's new Chief Executive Officer. Mr. Band replaces Shlomo Shalev who will continue as the Chairman of the Board of Directors. Previously, Mr. Band has served as the Chairman and Chief Executive Officer of Gix Internet Ltd. (formerly Algomizer Ltd.) a publicly traded technology company specializing in online marketing, and as the Chief Executive Officer of Dotomi (acquired by ValueClick), where he oversaw operations and strategic initiatives in the digital marketing space. From 2020 through its acquisition in 2023 he served as a board advisor to 7digital Group plc (formerly AIM: 7DIG), contributing to its strategic direction and corporate governance. He has also served as the Chief Executive Officer of Monitor2Heart, and also served as a Chairman of Viewbix Inc. (OTCMKTS: VBIX) from 2018 to 2020. He holds an MBA and a B.A. in Economics from The Hebrew University of Jerusalem.
공시 • Aug 16XTL Biopharmaceuticals Ltd. (TASE:XTLB) completed the acquisition of THE SOCIAL PROXY Ltd.XTL Biopharmaceuticals Ltd. (TASE:XTLB) entered into a binding term sheet to acquire THE SOCIAL PROXY Ltd. on March 19, 2024. In exchange, the XTL will issue a certain number of ADS's to Social Proxy shareholders, representing 44.6% of the company's share capital. Additionally, the company will pay $0.43 million to the shareholders of Social Proxy. The completion of the Transaction is subject to negotiation of definitive agreements, containing representations, warranties and covenants as well as the satisfaction of various conditions required prior to closing, all as are customary for transactions of this nature, including, without limitation, the satisfaction of the Company, in its sole discretion, of a due diligence into Social Proxy, the approval of the Transaction by the Company’s shareholders and receipt of necessary government or third-party approvals, if required. As of June 5, 2024, XTL Biopharmaceuticals Ltd. entered into a definitive share purchase agreement to acquire THE SOCIAL PROXY Ltd. In addition, as part of the Transaction, the shareholders of Social Proxy will be issued additional warrants, which may only be exercised upon reaching certain financial measured milestones within a period of up to three years from the closing of the Transaction. As per terms, Social Proxy will operate as fully owned subsidiary of the Company and its shareholders will be entitled to appoint two representatives to the Company’s board of directors out of a total of up to seven directors. XTL Biopharmaceuticals Ltd. (TASE:XTLB) completed the acquisition of THE SOCIAL PROXY Ltd. on August 14, 2024.
공시 • Jul 23XTL Biopharmaceuticals Ltd., Annual General Meeting, Jul 22, 2024XTL Biopharmaceuticals Ltd., Annual General Meeting, Jul 22, 2024. Location: doron tikotzky kantor gutman & amit gross, 7 metsada st., b.s.r tower 4, 33 floor, bnei brak Israel
공시 • Oct 21XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyXTL Biopharmaceuticals Ltd. announced that the Company received a written notification from the Nasdaq Stock Market LLC on October 18, 2023, notifying the Company that it is not in compliance with the minimum bid price requirement set in the Nasdaq Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of USD 1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's American Depositary Shares for the 30 consecutive business days from September 6, 2023, to October 17, 2023, the Company no longer meets the minimum bid price requirement. The Notification Letter does not impact the Company's listing on the Nasdaq Capital Market at this time and the Company's ADSs continue to trade on the Nasdaq Capital Market under the symbol "XTLB". In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until April 15, 2024, to regain compliance. The Notice states that to regain compliance, the bid price for the ADSs must close at USD 1.00 per ADS or more for a minimum of ten (10) consecutive business days during the compliance period ending April 15, 2024. In the event the Company does not regain compliance during the compliance period, the Company may be eligible for additional time. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse share split, if necessary. If the Company meets tese requirements, Nasdaq will inform the Company it has been granted an additional 180 calendar days to regain compliance with Nasdaq's current listing requirements. However, if it appears to Nasdaq that the Company will not be able to cure this deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Company's securities will be subject to delisting. The Company will continuously monitor the closing bid price of its ADSs between now and April 15, 2024, and will evaluate its options to regain compliance with Nasdaq Listing Rule 5550(a)(2) before such date. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price or maintain compliance with other Nasdaq listing standards.
New Risk • Jun 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (US$6.56m market cap). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).